Lexicon Pharmaceuticals (LXRX) News Today $0.35 +0.02 (+5.65%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$0.34 0.00 (-0.75%) As of 03/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Lexicon Pharmaceuticals (NASDAQ:LXRX) Now Covered by Analysts at StockNews.comStockNews.com started coverage on shares of Lexicon Pharmaceuticals in a research note on Friday. They set a "sell" rating for the company.March 28 at 2:14 AM | marketbeat.comCritical Review: Lexicon Pharmaceuticals (NASDAQ:LXRX) versus Bristol-Myers Squibb (NYSE:BMY)March 25 at 1:57 AM | americanbankingnews.comLexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated at StockNews.comMarch 22, 2025 | americanbankingnews.comLexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at StockNews.comStockNews.com assumed coverage on Lexicon Pharmaceuticals in a research report on Thursday. They issued a "sell" rating for the company.March 20, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for LXRX Q1 Earnings?Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - HC Wainwright issued their Q1 2025 EPS estimates for shares of Lexicon Pharmaceuticals in a report issued on Friday, March 7th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will post earnings per sharMarch 11, 2025 | marketbeat.comEquities Analysts Issue Forecasts for LXRX Q1 EarningsLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for Lexicon Pharmaceuticals in a report issued on Friday, March 7th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will post earnMarch 10, 2025 | marketbeat.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2024 Earnings Call TranscriptMarch 8, 2025 | msn.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Consensus Recommendation of "Hold" by BrokeragesLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) has been assigned a consensus recommendation of "Hold" from the five brokerages that are currently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and two have issued a bMarch 8, 2025 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Price Target Cut to $6.00 by Analysts at Piper SandlerPiper Sandler cut their price objective on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating on the stock in a research note on Friday.March 8, 2025 | marketbeat.comLexicon Pharmaceuticals’ Mixed Earnings Call: Achievements and ChallengesMarch 7, 2025 | tipranks.comLexicon Pharmaceuticals (NASDAQ:LXRX) Issues Earnings Results, Beats Expectations By $0.02 EPSLexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%.March 7, 2025 | marketbeat.comLexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025March 7, 2025 | gurufocus.comLexicon Pharmaceuticals (NASDAQ:LXRX) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPSLexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%.March 7, 2025 | marketbeat.comLexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025March 7, 2025 | globenewswire.comLexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Lowered by Leerink PartnrsLeerink Partnrs cut Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday.March 7, 2025 | marketbeat.comLexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ...March 7, 2025 | gurufocus.comQ4 2024 Lexicon Pharmaceuticals Inc Earnings Call TranscriptMarch 7, 2025 | gurufocus.comLexicon Pharmaceuticals Advances Pipeline Amid Financial GrowthMarch 6, 2025 | tipranks.comLexicon Pharmaceuticals, Inc. (LXRX) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | seekingalpha.comLexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 6, 2025 | globenewswire.comLeerink Partners Downgrades Lexicon Pharmaceuticals (LXRX)March 5, 2025 | msn.comLeerink Partners Reiterates Market Perform Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)Leerink Partners reiterated a "market perform" rating and set a $1.00 price objective on shares of Lexicon Pharmaceuticals in a report on Tuesday.March 5, 2025 | marketbeat.comLexicon Pharmaceuticals Q4 2024 Earnings PreviewMarch 5, 2025 | seekingalpha.comLexicon downgraded to Market Perform from Outperform at LeerinkMarch 4, 2025 | markets.businessinsider.comLexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025March 4, 2025 | globenewswire.comH.C. Wainwright Remains a Buy on Lexicon Pharmaceuticals (LXRX)March 4, 2025 | markets.businessinsider.comLexicon Pharmaceuticals (NASDAQ:LXRX) Earns "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $4.00 price target on shares of Lexicon Pharmaceuticals in a research report on Monday.March 3, 2025 | marketbeat.comNeedham & Company LLC Reaffirms "Hold" Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)Needham & Company LLC restated a "hold" rating on shares of Lexicon Pharmaceuticals in a research note on Monday.March 3, 2025 | marketbeat.comLexicon stock plummets following Phase 2b study resultsMarch 3, 2025 | au.investing.comLexicon Pharmaceuticals stock tumbles after clinical study resultsMarch 3, 2025 | in.investing.comLexicon Pharmaceuticals (LXRX) Stock Is Down: What's Going On?March 3, 2025 | benzinga.comLexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic PainMarch 3, 2025 | globenewswire.comLexicon Pharmaceuticals (LXRX) Projected to Post Quarterly Earnings on MondayLexicon Pharmaceuticals (NASDAQ:LXRX) will be releasing earnings before the market opens on Monday, March 10, Financial Modeling Prep reports.March 3, 2025 | marketbeat.comLexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating ...March 2, 2025 | gurufocus.comLexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating ...March 2, 2025 | gurufocus.comLexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic PainMarch 2, 2025 | globenewswire.comLexicon’s sotagliflozin shows cardiovascular efficacy in published studyFebruary 18, 2025 | markets.businessinsider.comPublished Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)February 18, 2025 | globenewswire.comH.C. Wainwright Keeps Their Buy Rating on Lexicon Pharmaceuticals (LXRX)February 14, 2025 | markets.businessinsider.comPromising Outlook for Lexicon Pharmaceuticals’ LX9211 as a Novel Treatment for Diabetic Peripheral Neuropathic PainJanuary 30, 2025 | markets.businessinsider.comLexicon Pharmaceuticals (NASDAQ:LXRX) Given Hold Rating at Needham & Company LLCNeedham & Company LLC reaffirmed a "hold" rating on shares of Lexicon Pharmaceuticals in a research note on Wednesday.January 30, 2025 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $4.00 target price on shares of Lexicon Pharmaceuticals in a research note on Wednesday.January 30, 2025 | marketbeat.comLexicon Pharmaceuticals jumps amid takeover speculationJanuary 29, 2025 | seekingalpha.comLexicon Pharmaceuticals' (LXRX) "Hold" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reissued a "hold" rating on shares of Lexicon Pharmaceuticals in a research note on Wednesday.January 29, 2025 | marketbeat.comLexicon Pharmaceuticals' (LXRX) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and issued a $4.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Wednesday.January 29, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and Allakos (ALLK)January 27, 2025 | markets.businessinsider.comLexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic PainJanuary 21, 2025 | globenewswire.comHere’s Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10January 6, 2025 | msn.comLexicon Pharmaceuticals, Inc.: Lexicon Appoints Scott Coiante as Chief Financial OfficerJanuary 2, 2025 | finanznachrichten.deLexicon Appoints Scott Coiante As CFO, SVPJanuary 2, 2025 | markets.businessinsider.com Remove Ads Get Lexicon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address LXRX Media Mentions By Week LXRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LXRX News Sentiment▼0.570.79▲Average Medical News Sentiment LXRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LXRX Articles This Week▼54▲LXRX Articles Average Week Remove Ads Get Lexicon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies EBS News VSTM News VNDA News XOMA News CDXS News IRWD News SGMO News ACHV News RGLS News DOMH News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LXRX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexicon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LXRX Stock Free LXRX Stock Alerts